within Pharmacolibrary.Drugs.ATC.C;

model C04AA31
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.7,
    Cl             = 2.0,
    adminDuration  = 600,
    adminMass      = 0.05,
    adminCount     = 1,
    Vd             = 0.0025,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.013333333333333334,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Bamethan is a vasodilator drug that has been used for the treatment of peripheral vascular disorders such as Raynaud's disease and arterial circulatory disorders. It is a sympathomimetic amine structurally related to amphetamine. Bamethan has limited contemporary clinical use and is not widely approved or used in modern medicine.</p><h4>Pharmacokinetics</h4><p>No published pharmacokinetic studies were found for bamethan in humans or animals. The following values are estimations based on general characteristics of orally administered amphetamine-like sympathomimetics in adult healthy individuals.</p><h4>References</h4><ol><li><p>Hengstmann, JH, &amp; Steinkamp, B (1981). [Pharmacokinetics of 3H-bamethan in humans]. <i>Arzneimittel-Forschung</i> 31(5) 843–848. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/6115653/&quot;>https://pubmed.ncbi.nlm.nih.gov/6115653</a></p></li><li><p>Miller, RB (1991). A validated high-performance liquid chromatographic method for the determination of atenolol in whole blood. <i>Journal of pharmaceutical and biomedical analysis</i> 9(10-12) 849–853. DOI:<a href=&quot;https://doi.org/10.1016/0731-7085(91)80012-x&quot;>10.1016/0731-7085(91)80012-x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/1822203/&quot;>https://pubmed.ncbi.nlm.nih.gov/1822203</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end C04AA31;
